Acadian Asset Management’s Whitehawk Therapeutics WHWK Stock Holding History

Acadian Asset Management’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$778K	Buy	170,883 +100,782	+144%	+$419K	﹤0.01%	1339
2026 Q1	$239K	Buy	70,101 +45,467	+185%	+$142K	﹤0.01%	1539
2025 Q4	$58K	Sell	24,634 -1,572	-6%	-$3.61K	﹤0.01%	1768
2025 Q3	$49K	Buy	+26,206	New	+$48.2K	﹤0.01%	1648
2021 Q4	–	Sell	-20,343	Closed	-$597K	–	1882
2021 Q3	$597K	Sell	20,343 -84,493	-81%	-$2.58M	﹤0.01%	996
2021 Q2	$2.66M	Sell	104,836 -22,596	-18%	-$516K	0.01%	631
2021 Q1	$2.47M	Buy	127,432 +26,798	+27%	+$617K	0.01%	677
2020 Q4	$1.48M	Buy	100,634 +21,912	+28%	+$469K	0.01%	859
2020 Q3	$1.77M	Buy	+78,722	New	+$1.66M	0.01%	703
2019 Q4	–	Sell	-12,437	Closed	-$127K	–	2094
2019 Q3	$127K	Hold	12,437	–	–	﹤0.01%	1431
2019 Q2	$170K	Buy	12,437 +2,342	+23%	+$35.5K	﹤0.01%	1265
2019 Q1	$137K	Buy	10,095 +9,000	+822%	+$387K	﹤0.01%	1445
2018 Q4	$28K	Buy	+1,095	New	+$34.9K	﹤0.01%	1518

Other funds holding WHWK

Yu Fan $108M AUM 137.54% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $136M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management's WHWK Position: Q2 2026 in Review

Acadian Asset Management increased its Whitehawk Therapeutics (WHWK) stake by 144% in Q2 2026, buying an estimated $419K and bringing the position to 170,883 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

Acadian Asset Management first reported a position in WHWK in Q4 2018 and has held it in 13 quarters since. The position peaked at $2.66M in Q2 2021. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

Acadian Asset Management held 170,883 shares of Whitehawk Therapeutics worth $778K as of Q2 2026.
Acadian Asset Management bought 100,782 Whitehawk Therapeutics shares in Q2 2026, an estimated $419K.
Whitehawk Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1339 holding.
Acadian Asset Management first reported a position in Whitehawk Therapeutics in Q4 2018 and has held it in 13 quarters since.
Acadian Asset Management's Whitehawk Therapeutics position peaked at $2.66M in Q2 2021.
77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.